Amorphous solid dispersions typically improve the oral bioavailability of poorly soluble
drugs. However, residual crystallinity is always a concern, in terms of potential impact on the …

USPC.................................................. 424/464 489 (7) ABSTRACT See application file for
complete search history. A modified release composition comprising tacrolimus releases …

(57) ABSTRACT A method for the preparation of a pharmaceutical particulate composition
for modified release of one or more therapeu tically, prophylactically and/or diagnostically …

An extended release oral dosage form comprising as active Substance tacrolimus or a
pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a …

(57) ABSTRACT A medical device comprising a Supporting structure capable of containing
or Supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient …

Synergistic combinations of a macrollide T-cell immuno modulator or immunosuppressant
Such as 33-epichloro-33 desoxyascomycin and an emollient such as dimethicone, glycerol …

US7994214B2 - Solid dispersions comprising tacrolimus - Google Patents US7994214B2 -
Solid dispersions comprising tacrolimus - Google Patents Solid dispersions comprising …

3,843,787 A 10, 1974 Fabrizio 4,312,866 A 1, 1982 Caruso 4.331, 803 A 5, 1982 Watanabe
et al. 4.474, 768 A 10/1984 Bright 4,742,049 A 5, 1988 Baker et al. 4,886,792 A 12/1989 …

5,498,702 A 3, 1996 Mitchell et al. diseases such as cancer. The compositions comprise one
or 5,502,199 A 3/1996 Angerbauer et al. more polysaccharides in an admixture with one or …

An extended release oral dosage form comprising as active substance tacrolimus or a
pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a …